http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005073248-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db628fbc812ea146bb6eb24a8c0ab43a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b218427b8965cba2bcd3ebc69d3fa971 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4713 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate | 2005-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3b3aeda995fa0b54bafde9026416215 |
| publicationDate | 2005-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005073248-A1 |
| titleOfInvention | Peptides for treatment of autoimmune diseases |
| abstract | Peptides for use in the therapy or prevention of Type 1 Diabetes mellitus (TIDM) are those having sequences containing QPLALEGSLQK (SEQ ID NO: 9). j Examples are those having a sequence selected from the group consisting 10 essentially of GGGPGAGSLQPLALEGSLQK (SEQ ID NO: 4), GSLQPLALEGSLQKRGIV (SEQ ID NO: 5), and QPLALEGSLQKRGIVEQ (SEQ ID NO: 6). One or more of the above peptides may be combined with one or more peptides having a sequence or sequences consisting essentially of sequences selected from LAKEWQALCAYQAEPNTCATAQGI<GNIK (SEQ ID NO: 11), KLKVESSPSRSDYINASPIIEHDP (SEQ ID NO: 12), and SFYLKNVQTQETRTLTQFHF (SEQ ID NO: 13). Also disclosed is a method of assessing the potential of a peptide for TIDM therapy or prevention which comprises subjecting the candidate peptide to a frst assay indicative of a pathogenic T cell response in blood or other biological sample, such as an ELISPOT assay for IFN-y. In the case of a positive response to the first assay, the candidate peptide is subjected to a second assay indicative of a regulatory T cell response to the peptide, such as an ELISPOT assay for IL 10). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009004315-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016275295-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007032778-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007032778-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018524301-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400131-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8906383-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016162495-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016198887-A1 |
| priorityDate | 2004-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 250.